Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

ABSTRACT:

Background

Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer. Mutations in the ERBB2 receptor have recently been reported in breast cancer at diagnosis and also in gastric, colorectal and lung cancer. These mutations may have an impact on the clinical responses achieved with lapatinib in breast cancer and may also have a potential impact on the use of lapatinib in other solid cancers. However, the sensitivity of lapatinib towards clinically observed ERBB2 mutations is not known.

Methodology/principal findings

We cloned a panel of 8 clinically observed ERBB2 mutations, established stable cell lines and c

SUBMITTER: Kancha RK 

PROVIDER: S-EPMC3203921 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature